Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159716 · ClinicalTrials.gov registry record · Phase 1
CART-meso in Mesothelin Expressing Cancers
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02159716: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT02159716 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02159716, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
Phase I study to establish safety and feasibility of intravenously administered lentiviral transduced CART-meso cells administered with and without cyclophosphamide in a 3+3 dose escalation design in patients with metastatic pancreatic cancer, serous epithelial ovarian cancer, or pleural mesothelioma. Dose: 1-3xE7 /mE2 (Cohort 1 and 2) and 1-3xE8 /mE2 (Cohort 3 and 4 ) CAR+ T cells by intravenous route. In the event of 2 DLTs at each dose level, we will dose deescalate by 10-fold.
Interventions
- BIOLOGICAL CART-meso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159716
The ClinicalTrials.gov registry entry for NCT02159716 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CART-meso is the first listed.
NCT02159716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02159716 about?
NCT02159716 is a clinical study titled "CART-meso in Mesothelin Expressing Cancers". Phase I study to establish safety and feasibility of intravenously administered lentiviral transduced CART-meso cells administered with and without cyclophosphamide in a 3+3 dose escalation design in patients with metastatic pancreatic cancer, serous epithelial ovarian cancer, or pleural mesotheliom...
What is the current status of trial NCT02159716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-06. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02159716?
The interventions under investigation include: CART-meso (BIOLOGICAL).
Who is sponsoring clinical trial NCT02159716?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.